PO.6.137 Design of a phase 2, multicenter, randomized, placebo-controlled, parallel-group, double-blind study to assess the efficacy and safety of nipocalimab in adults with active systemic lupus erythematosus

• T Rooney,
• R Gordon,
• G Vratsanos,
• C Calderon,
• S Gao,
• RW Hoffman,
• F Zazzetti,
• F Liu-Walsh,
• B Van Hartingsveldt,
• Q Zuraw,
• JH Leu,
• A Berhanu Debella

Affiliations

T Rooney

7Eli Lilly & Company, Indianapolis, IN, USA

R Gordon

3Townsville Sexual Health Services, Queensland, Australia

G Vratsanos

Bristol-Myers Squibb, Princeton, New Jersey, USA

C Calderon

Hospital Universitario de Mostoles, Pharmacy, Mostoles (Madrid), Spain

S Gao

Department of Chest Surgery, Cancer Hospital, Peking Union Medical College and Chinese Academy of Medical Science, Beijing, China

RW Hoffman

1Eli Lilly and Company, Immunology, Indianapolis, USA

F Zazzetti

3Janssen Medical Affairs Global Services, LLC ~ Buenos Aires ~ Argentina

F Liu-Walsh

1Janssen Research and Development, LLC ~ Spring House ~ USA

B Van Hartingsveldt

2Janssen Biologics Europe ~ Leiden ~ Netherlands

Q Zuraw

3Janssen-Cilag Argentina ~ Buenos Aries ~ Argentina

JH Leu

1Janssen Research and Development, LLC ~ Spring House ~ USA

A Berhanu Debella

1Janssen Research and Development, LLC ~ Spring House ~ USA